Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, March 17, 2015, 79 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $428.00 to $8,749,928.65.

Highlighted Stocks Traded by Insiders:

Biogen Idec (BIIB) - FREE Research Report

DiPietro Kenneth, who is EVP Human Resources at Biogen Idec, sold 803 shares at $415.46 on March 17, 2015. Following this transaction, the EVP Human Resources owned 0 shares meaning that the stake was reduced by 100% with the 803-share transaction.

The shares most recently traded at $420.70, up $5.24, or 1.25% since the insider transaction. Historical insider transactions for Biogen Idec go as follows:

  • 4-Week # shares sold: 5,073
  • 12-Week # shares sold: 11,288
  • 24-Week # shares sold: 21,213

The average volume for Biogen Idec has been 1.6 million shares per day over the past 30 days. Biogen Idec has a market cap of $98.8 billion and is part of the health care sector and drugs industry. Shares are up 25.53% year-to-date as of the close of trading on Tuesday.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. The company has a P/E ratio of 34.1. Currently, there are 12 analysts who rate Biogen Idec a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BIIB - FREE

TheStreet Quant Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Biogen Idec Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Seattle Genetics (SGEN) - FREE Research Report

Cline Darren S, who is SVP, Commercial at Seattle Genetics, sold 7,500 shares at $38.65 on March 17, 2015. Following this transaction, the SVP, Commercial owned 33,135 shares meaning that the stake was reduced by 18.46% with the 7,500-share transaction.

The shares most recently traded at $38.87, up $0.22, or 0.57% since the insider transaction. Historical insider transactions for Seattle Genetics go as follows:

  • 4-Week # shares sold: 2,693
  • 12-Week # shares sold: 1,452
  • 24-Week # shares sold: 1,452

The average volume for Seattle Genetics has been 1.2 million shares per day over the past 30 days. Seattle Genetics has a market cap of $4.9 billion and is part of the health care sector and drugs industry. Shares are up 21.07% year-to-date as of the close of trading on Tuesday.

Seattle Genetics, Inc., a biotechnology company, develops and commercializes antibody-based therapies for the treatment of cancer. Currently, there are 6 analysts who rate Seattle Genetics a buy, 2 analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SGEN - FREE

TheStreet Quant Ratings rates Seattle Genetics as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and generally disappointing historical performance in the stock itself. Get the full Seattle Genetics Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

DCT Industrial (DCT) - FREE Research Report

Pharris John V, who is Managing Director at DCT Industrial, sold 4,255 shares at $34.40 on March 17, 2015. Following this transaction, the Managing Director owned 21,045 shares meaning that the stake was reduced by 16.82% with the 4,255-share transaction.

The shares most recently traded at $34.47, up $0.07, or 0.2% since the insider transaction. Historical insider transactions for DCT Industrial go as follows:

  • 4-Week # shares sold: 23,610
  • 12-Week # shares sold: 23,610
  • 24-Week # shares sold: 38,532

The average volume for DCT Industrial has been 1.2 million shares per day over the past 30 days. DCT Industrial has a market cap of $3.0 billion and is part of the financial sector and real estate industry. Shares are down 3.56% year-to-date as of the close of trading on Tuesday.

DCT Industrial Trust Inc. operates as a publicly owned real estate investment trust. The firm provides its services to companies. Through its fund, it engages in the ownership, operation, and development of real estate properties. The stock currently has a dividend yield of 3.25%. The company has a P/E ratio of 66.2. Currently, there are 4 analysts who rate DCT Industrial a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DCT - FREE

TheStreet Quant Ratings rates DCT Industrial as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, compelling growth in net income, increase in stock price during the past year and notable return on equity. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full DCT Industrial Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null